Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene

Study Overview
=================
Brief Summary
-----------------
Investigation of two transdermal hormone patch formulations for contraception regarding inhibition of ovulation over a period of 3 treatment cycles in healthy young female volunteers

Detailed Description
-----------------
Study was suspended due to inconclusive toxicology findings regarding the used patch formulation to be clarified prior to re-start of the study.

Official Title
-----------------
Multicenter, Open-label, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg EE and Either 1.05 or 2.1 mg GSD in Healthy Young Female Vol. Over a Period of 3 Treatment Cycles

Conditions
-----------------
Contraception, Ovulation Inhibition

Intervention / Treatment
-----------------
* Drug: Ethinylestradiol/Gestodene (BAY86-5016)
* Drug: Ethinylestradiol/Gestodene (BAY86-5016)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent, BMI: 18 - 30 kg/m², Healthy female volunteers, Age 18-35 years (smoker not older than 30 years, inclusive), Ovulatory pre-treatment cycle, at least 3 month since delivery, Abortion or lactation before the first screening examination, Willingness to use non-hormonal methods of contraception during entire study Exclusion Criteria: Contraindications for use of combined (estrogen/gestodene) contraceptive (e.g. history of venous/arterial thromboembolic disease Regular intake of medication other than OCs Clinically relevant findings (blood pressure, physical and gynaecological examination, laboratory examination) Anovulatory pre-treatment cycle

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Ethinylestradiol/Gestodene (BAY86-5016)<br>* transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)<br>|
| Experimental: Arm 2<br> | Drug: Ethinylestradiol/Gestodene (BAY86-5016)<br>* transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary efficacy variable will be the proportion of volunteers with ovulation in at least one of the treatment cycles 2 and 3. |  | 4 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of ovarian activity during treatment cycle2 and 3 (Hoogland score) |  | 4 month | 
| Course of gonadotropins (FSH, LH, P, E2) |  | 4 month | 
| Endometrial thickness |  | 4 month | 
| Follicle size |  | 4 month | 
| Pharmacokinetics of EE, GSD and SHBG in treatment cycles 2 and 3 |  | 4 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Female Contraception, Ovulation Inhibition